



Universiteit
Leiden
The Netherlands

Celiac disease : how complicated can it get?

Tjon, J.M.L.

Citation

Tjon, J. M. L. (2011, November 30). *Celiac disease : how complicated can it get?*. Retrieved from <https://hdl.handle.net/1887/18156>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/18156>

Note: To cite this publication please use the final published version (if applicable).

CELIAC DISEASE

How complicated can it get?

CELIAC DISEASE

How complicated can it get?

PROEFSCHRIFT

ter verkrijging van
de graad van Doctor aan de Universiteit Leiden,
op gezag van Rector Magnificus prof.mr. P.F. van der Heijden,
volgens besluit van het College voor Promoties
te verdedigen op woensdag 30 november 2011
klokke 16.15 uur

door

Jennifer May-Ling Tjon

geboren te Leiden, 18-10-1980

PROMOTIECOMMISSIE

<i>Promotor:</i>	Prof.dr. F. Koning	
<i>Copromotor:</i>	Dr. J. van Bergen	
<i>Overige leden:</i>	Prof.dr. P.J. van den Elsen	
	Prof.dr. C. Wijmenga	<i>Rijksuniversiteit Groningen</i>
	Dr. G. Bouma	<i>Vrije Univerisiteit Amsterdam</i>
	Dr. M.H. Vermeer	



The studies described in this thesis were performed at the Departement of Immunohematology and Blood Transfusion, Leiden University Medical Center.

This work was supported by the Celiac Disease Consortium, an Innovative Cluster approved by The Netherlands Genomics Initiative and partially funded by the Dutch government (BSIK03009) and by the Dutch Digestive Disease Foundation ("Maag Lever Darm stichting", grant WO 06-21).

Financial support for the publication of this thesis was provided by the Celiac Disease Consortium and the Nederlandse Coeliakie Vereniging.

The Nederlandse Coeliakie Vereniging supports scientific research. Also, the NCV organizes contact amongst fellow-sufferers, offers and spreads information, informs and is active in advocacy for persons with coeliac disease or dermatitis herpetiformis (www.glutenvrij.nl).

Printing: Ridderprint
ISBN: 978-90-5335-480-3

Layout: Heiko Locher
Cover design: Heiko Locher & Jennifer Tjon

About the cover: Abberant IEL lyses intestinal epithelial cells.

© Jennifer Tjon 2011

All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission from the autor.

CONTENTS

SCOPE OF THIS THESIS	
CHAPTER 1	13
GENERAL INTRODUCTION	
CELIAC DISEASE: HOW COMPLICATED CAN IT GET?	
CHAPTER 2	33
DEFECTIVE SYNTHESIS OR ASSOCIATION OF T CELL RECEPTOR CHAINS UNDERLIES LOSS OF SURFACE T CELL RECEPTOR-CD3 EXPRESSION IN ENTEROPATHY-ASSOCIATED T CELL LYMPHOMA	
CHAPTER 3	53
DNAM-1 MEDIATES EPITHELIAL CELL-SPECIFIC CYTOTOXICITY OF ABERRANT INTRAEPITHELIAL LYMPHOCYTE LINES FROM REFRACTORY CELIAC DISEASE TYPE II PATIENTS	
CHAPTER 4	75
SYNERGISTIC EFFECT OF IL-15 AND CD30-STIMULATION ON IFN- γ SECRETION BY ABERRANT INTRAEPITHELIAL LYMPHOCYTES	
CHAPTER 5	87
CHARACTERIZATION OF A UNIQUE CD3 ⁻ CD7 ⁺ INTRAEPITHELIAL LYMPHOCYTE POPULATION: POSSIBLE ORIGIN OF ABERRANT INTRAEPITHELIAL LYMPHOCYTES IN REFRACTORY CELIAC DISEASE TYPE II	
CHAPTER 6	107
GENERAL DISCUSSION	
NEDERLANDSE SAMENVATTING	
CURRICULUM VITAE	
LIST OF PUBLICATIONS	
DANKWOORD	

SCOPE OF THIS THESIS

SCOPE OF THIS THESIS

Celiac disease (CD) is a common inflammatory disorder of the small intestine, which is triggered by ingested gluten proteins. Previous studies identified crucial steps in the development of celiac disease and based on this knowledge, we propose a threshold model for the development of celiac disease, which is described in chapter 1. It has also become clear that adult-onset celiac disease has a higher frequency of developing complications: refractory celiac disease (RCD) and enteropathy associated T cell lymphoma (EATL). About a decade ago, RCD was subdivided into RCD type I and RCD type II. This division was based on the respective absence or presence of an aberrant intraepithelial lymphocyte (IEL) population. These aberrant IELs were defined as surface TCR-CD3⁺CD4⁺CD8⁻CD7⁺CD103⁺, intracellular CD3⁺ cells and were identified as the missing link between regular IELs in uncomplicated celiac disease and lymphoma cells in EATL. The function and cellular origin of the aberrant IELs, however, remained unclear. The aim of this thesis was, therefore, to gain more insight in the phenotypical and functional characteristics of aberrant IELs as this might help to understand the events leading from uncomplicated CD to RCD II and gastrointestinal lymphoma.

Chapter 1 provides an overview of the pathogenesis of uncomplicated CD, including the involvement of the disease predisposing HLA-DQ2 and HLA-DQ8 molecules and their role in the presentation of gluten derived peptides. Based on the available data we propose a threshold model in which the efficiency of gluten presentation to CD4⁺ T cells determines the likelihood of developing CD and its complications.

Until recently, aberrant IELs were mainly investigated in situ due to lack of model systems. This limited the type and extent of experiments to investigate molecular events linked to the development of RCD II and EATL. In *chapter 2* we describe the isolation and propagation of three cell lines from duodenal biopsies of three individual RCD II patients that display a surface TCR-CD3⁺CD4⁺CD8⁻CD7⁺CD103⁺, intracellular CD3⁺ phenotype that is characteristic for the aberrant cells found in patients with RCD II. We used these cell lines as a model for aberrant IELs in all the studies described in this thesis. In *chapter 2* we studied the presence and functionality of the individual TCR and CD3 chains.

In active celiac disease, regular TCR⁺ IELs acquire an NK cell receptor repertoire through which they can lyse epithelial cells. Much less is known about the contribution of aberrant IELs to tissue damage in RCD II and EATL. In *chapter 3* we used the RCD cell lines to investigate the specificity of cytotoxicity of aberrant IELs and the receptors involved.

In *chapter 4* we studied the ability of the RCD cell lines to secrete cytokines after triggering with an array of stimuli. This chapter also suggests a novel role for the activation marker CD30 on (pre)malignant IELs in RCD II and EATL.

The exact cellular origin of aberrant IELs is still unclear. From *chapter 2* we learned that intracellular, all CD3 chains were present, whereas the TCR chains were not always present. Furthermore, the CD3 complex was functional as introduction of exogenous TCR chains resulted in surface TCR-CD3 expression. In *chapter 5* we performed genomic,

transcriptomic and flowcytometric analysis of the RCD cell lines as a further step to determine the cellular origin of aberrant IELs. We demonstrate that cells with an “aberrant” phenotype are present in the intestinal epithelium of healthy individuals as well. This led us to propose that such cells are part of the normal lymphocyte repertoire and most likely the precursors of the monoclonal aberrant cell populations found in patients with RCD II and EATL. Moreover, these data indicate that aberrant IELs are not derived from mature T cells.

In *chapter 6* the relevance of this thesis and directions for further research and future therapeutic possibilities are discussed.

